AR and neoplasm: Patients resistant to bicalutamide usually can respond to enzalutamide, a second-generation AR antagonist, which has better anti-tumor efficacy than bicalutamide, because of its higher affinity for AR, ability to inhibit nuclear translocation, gene binding, and recruitment of coregulators (73, 74).